I have been talking about treatments for COVID-19 for nearly 15 months based on published data in the gold standard randomized clinical trials. What I will say here isn't new; it is all in my book but will repeat in this thread because there are questions on plasma and remdesivir

1. COVID-19 is not a disease that everyone experiences equally.
2. There are different phases of COVID-19.
3. There is no magic bullet drug for COVID-19.
4. Some drugs are palliative.

We have to remember these four points. I've stressed them repeatedly for over a year now.

What you should realize are three points, if nothing else.
1. Disease treatment during a pandemic is a moving target.
2. There is a narrow window- a "Goldilocks moment" to treat a particular kind of patient effective with a drug.
3. Clinical trials are hard and often inconclusive

This visual shows the presymptomatic, symptomatic COVID-19, and post acute phases. Not all people go through the later phases.

You can see the windows of opportunity for various therapeutics. It explains why no single drug is a magic bullet. (Source J. Antimicrob. Chemother.)

The second visual I'd like to share is a table from JAMA that summarizes acute COVID-19, later hyperinflammatory illness in certain people, and Long COVID.

The first few months, the focus was almost exclusively on acute disease, but now we know more about other aspects.

Your own doctor is the best person to advise you, not any other doctor or any other random person on the internet saying in general terms something works or it doesn't. That said we can look at the NIH expert panel guidelines which have been updated many times over the last year.

Here are the five major published trials for remdesivir summarized in a table format with trial goals, participants, outcome, limitations, and interpretation. https://www.covid19treatmentguidelines.nih.gov/tables/table-2a/

Here are twelve major published trials for convalescent plasma summarized with trial goals, participants, outcome, limitations, and interpretation. https://www.covid19treatmentguidelines.nih.gov/tables/table-3b/

Based on all of these studies the NIH expert panel finds a limited use for remdesivir in certain cases.

Remdesivir is currently the ONLY US FDA-approved antiviral small molecule drug for the treatment of COVID-19 (not ivermectin, not hydroxychloroquine, not favipiravir).

As far as convalescent plasma, the NIH panel advises AGAINST the use of low-titre convalescent plasma or plasma in immunocompromised patients because of the potential rise of variants.

I have written about plasma and the rise of variants of concern: https://twitter.com/bhalomanush/status/1384878160047656966?s=20

Major trials (including a stellar one conducted in India) have shown no or unknown benefit with convalescent plasma.